Open AccessMedulloblastoma epigenetics and the path to clinical innovation
Author(s) -
Amanda R. Haltom,
Stephanie Toll,
Donghang Cheng,
Satoru Maegawa,
Vidya Gopalakrishnan,
Soumen Khatua
Publication year - 2020
Publication title -
journal of neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.256
H-Index - 114
eISSN - 1573-7373
pISSN - 0167-594X
DOI - 10.1007/s11060-020-03591-9
Subject(s) - epigenetics , medulloblastoma , microrna , dna methylation , biology , histone , context (archaeology) , computational biology , bioinformatics , genetics , gene , gene expression , paleontology
In the last decade, a number of genomic and pharmacological studies have demonstrated the importance of epigenetic dysregulation in medulloblastoma initiation and progression. High throughput approaches including gene expression array, next-generation sequencing (NGS), and methylation profiling have now clearly identified at least four molecular subgroups within medulloblastoma, each with distinct clinical and prognostic characteristics. These studies have clearly shown that despite the overall paucity of mutations, clinically relevant events do occur within the cellular epigenetic machinery. Thus, this review aims to provide an overview of our current understanding of the spectrum of epi-oncogenetic perturbations in medulloblastoma.